CLINICAL TRIALS FOR GRIN2B
Participating in clinical trials is an important way to help accelerate therapeutic development. Find more information about the study and future studies below.
GRIN THERAPEUTICS: RAD-GRIN-101
BEELINE STUDY – ENROLLING
ClinicalTrials.gov ID – NCT07224581
The Phase 3 portion of Study RAD-GRIN-101 is a multinational, multicenter, randomized, double-blind, placebo-controlled trial followed by an open-label extension to evaluate the efficacy and safety of radiprodil in participants with GRIN-related neurodevelopmental disorder (GRIN-NDD) with a gain-of-function (GoF) genetic variant.
This study will enroll two cohorts: one cohort of participants with a minimal number of countable motor seizures (with or without behavioral symptoms) (Phase 3 Cohort 1: Qualifying Seizures Cohort); and a second cohort with disease symptoms but no seizures or fewer seizures than required for the Qualifying Seizures Cohort (Phase 3 Cohort 2: Without Qualifying Seizures Auxiliary Cohort).
Read the results of the Phase 1 trial here.
Learn how to enroll here.
LUNDBECK: DEEP OCEAN STUDY
The DEEp Ocean Study is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with Developmental Epileptic Encephalopathy. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
Learn how to enroll here.
PRAXIS PRECISION MEDICINES: EMERALD STUDY
The EMERALD study is evaluating a potential new treatment to reduce seizures caused by Developmental and Epileptic Encephalopathies (DEEs). Relutrigine is an investigational medicine that can be taken orally or administered through a G/J tube. Relutrigine is designed to regulate sodium flow in brain cells by targeting overactive sodium channels that cause seizures; therefore, potentially offering better seizure control with fewer side effects. Relutrigine has been designed to maximize its effects against overactive sodium channels that are believed to cause seizure activity while minimizing the blocking of normal activity needed for healthy brain function.
Learn how to enroll here.
Disclaimer – GRIN2B Foundation is passing this information along to you for information purposes; please check with your doctor first to see if your child should participate.